<DOC>
	<DOCNO>NCT01288209</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety TMC435 combination peginterferon alfa-2a ( PegIFNα-2a ) ribavirin genotype 1 hepatitis C virus ( HCV ) -infected participant fail respond previous interferon ( IFN ) -based therapy Japan .</brief_summary>
	<brief_title>A Phase III Study TMC435 Genotype 1 , Hepatitis C-infected Participants Who Failed Respond Previous IFN-based Therapy</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , 2-arm , open-label study evaluate efficacy safety TMC435 ( also refer jnj-38733214-aaa ) combination standard care ( SoC ) therapy consist peginterferon alfa-2a ( PegIFNα-2a ) ribavirin ( RBV ) administer accord manufacturer 's prescribe information adult , genotype 1 hepatitis C virus ( HCV ) -infected participant fail respond previous interferon ( IFN ) -based therapy Japan . The study objective evaluate efficacy TMC435 proportion participant undetectable HCV ribonucleic acid ( RNA ) . Participants receive 12 week treatment TMC435 ( 100 mg ) daily plus PegIFNα-2a ( P ) RBV P ) follow 12 36 week treatment PR OR participant receive 24 week treatment TMC435 ( 100 mg ) daily plus PR follow 24 week treatment PR . TMC435 100-mg capsule take orally ( via mouth ) . Treatment PR last 24 48 week : Pegylated interferon supply vial contain 1.0 mL solution 180 mcg PegIFNα-2a inject syringe skin weekly . Ribavirin give 200-mg tablet ( daily dose : 600-1000 mg base body weight ) , take orally mouth two time day meal . Participants receive oral capsule TMC435 ( 100 mg ) daily Week 12 24 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Participant must chronic genotype 1 HCV infection HCV RNA level &gt; = 5.0 log10 IU/mL Participant fail respond previous IFNbased therapy Participant must willing use contraceptive measure time inform consent 6 month last dose study medication . Coinfection HCV genotype coinfection human immunodeficiency virus ( HIV ) Diagnosed hepatic cirrhosis hepatic failure A medical condition contraindication PegIFNα2a ribavirin therapy History , current medical condition could impact safety patient study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis C virus</keyword>
	<keyword>Interferon Alfa-2a</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Viral RNA</keyword>
</DOC>